{ }
001122334455554433221100
001122334455554433221100

Roche advances subcutaneous Lunsumio in lymphoma amid competitive CAR-T landscape

Roche's subcutaneous Lunsumio has shown comparable efficacy to its intravenous version in treating follicular lymphoma, with an overall response rate of 76.6% versus 81.1% for IV. The new formulation offers advantages in administration time and safety, with lower rates of adverse events and cytokine release syndrome. Roche is also advancing its bispecific therapies, including trials for Lunsumio in combination with other treatments for diffuse large B-cell lymphoma.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.